QUICK TAKE VIDEO SUMMARY

RNAi Inhibitor of PCSK9

High LDL cholesterol is a major risk factor for cardiovascular disease. Reducing circulating PCSK9 levels with PCSK9 antibodies has been shown to reduce LDL cholesterol but has a short duration of effect. Is there a longer-acting agent? New research findings are summarized in a short video.